Investor Presentaiton

Large and Underpenetrated Global OSA and HGNS Market Opportunity Worldwide Obstructive Sleep Apnea Prevalence • Hypoglossal Nerve Stimulation Market Opportunity 936 Million 936M individuals (30-69 year) are estimated to suffer from OSA¹ >1 million eligible annually in key geographies US: 510,000 eligible patients annually Europe: 500,000 eligible patients annually • 425 Million 425M suffer from moderate to severe OSA, requiring therapy¹ Increasing prevalence of OSA due to rise in obesity Significant OSA comorbidities, including cardiovascular disease and type II diabetes Undiagnosed OSA 80% ~60,000 received HGNS as treatment First HGNS CE-Mark approval in 2010 - FDA authorization in 2014 Low awareness on neurostimulation as an OSA solution • Limited reimbursement 20% Only 20% OSA patients are diagnosed² 1. Benjafield, Adam V et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med 2019 2. Harvard Medical School Division of Sleep Medicine, The Price of Fatigue - The surprising economic costs of unmanaged sleep apnea, December 2010 3. Presents annual revenue growth for Inspire Medical. Inspire Medical corporate presentation - February 2024 5 +67% CAGR HGNS revenue 2017 - 20233 Endorsed by the global sleep and ENT medical communities Accepted by US/EU payors Embraced by OSA patient association groups Nyxoah™

View entire presentation